Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
|
31320555 |
2020 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clinical trials, and they were further discovered to have synergistic interactions.
|
30594434 |
2019 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Translocation t(11;14) has emerged as the first predictive marker in MM, indicating susceptibility to BCL2 inhibition.
|
31818702 |
2019 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Ex vivo pharmacodynamic analyses demonstrated that the combination of JQ1 and ricolinostat led to significantly lower MM cell proliferation and increased apoptosis and diminished expression of c-MYC and BCL-2.
|
31015208 |
2019 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Exosome-transmitted LINC00461 promotes multiple myeloma cell proliferation and suppresses apoptosis by modulating microRNA/BCL-2 expression.
|
30409700 |
2019 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, miR‑497 suppressed MM cell proliferation and promoted apoptosis by directly targeting Bcl‑2 and altering the expression of downstream apoptosis‑related proteins.
|
30535471 |
2019 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Co-culture experiments resulted in MDSC-induced AMPK phosphorylation in MM cells, which was associated with an increase in the anti-apoptotic factors MCL-1 and BCL-2, and the autophagy-marker LC3II.
|
30419344 |
2019 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, miR-324-5p potentiated the anti-MM efficacy of bortezomib through regulating the activities of multidrug-resistance proteins and the expression of Bcl-2 family genes.
|
28905994 |
2018 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Venetoclax, an oral BH3 mimetic inhibiting BCL2, showed single agent activity in MM with t(11;14), and is being studied in combination with bortezomib/dexamethasone.
|
29257139 |
2018 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ABT-199 is a specific Bcl-2 inhibitor in clinical trials for MM; however, its activity as a single agent was limited to myeloma patients with the t(11;14) translocation who acquire resistance due to co-expression of Mcl-1 and Bcl-xL.
|
29761903 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review addresses the role and regulation of pro-survival BCL-2 family proteins during healthy PC differentiation and in MM, as well as their potential as therapeutic targets.
|
30524962 |
2018 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Approximately, 20% of myeloma patients will exhibit <i>t</i> (11;14) associated with high BCL-2 expression making venetoclax an attractive therapeutic option.
|
30428277 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In myeloma, in vitro sensitivity to venetoclax is mainly observed in plasma cells harboring the t(11;14) translocation, a molecular subgroup associated with high Bcl-2 and low Mcl-1/Bcl-XL expression.
|
30076373 |
2018 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BCL-2 mRNA was significantly higher in the bone marrow mononuclear cells from MM patients.
|
30170425 |
2018 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The transcription of several gene products was found to be either commonly overexpressed (i.e., RKIP, Bcl-2, and DR5) or underexpressed (i.e., Bcl-6 and TNFR2) in both pre-MM and MM.
|
28476134 |
2017 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MM.1R and MM.1S cell lines were treated with 15d-PGJ<sub>2</sub> at 1-10μM and evaluated with regard to proliferation, mRNA expression of PRDX1, PRDX4, GRP78, GRP94, CHOP, BCL-2 and BAX.
|
28506771 |
2017 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in multiple myeloma (MM) cells, particularly in those harboring t(11;14), which express high levels of BCL-2 relative to BCL-X<sub>L</sub> and MCL-1.
|
29018077 |
2017 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The antiapoptotic proteins BCL-2 and myeloid cell leukemia sequence 1 (MCL-1) promote multiple myeloma (MM) cell survival.
|
28847998 |
2017 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ASA may potentiate the antimyeloma activity of BTZ against myeloma cells via suppression of AKT phosphorylation, survivin and Bcl-2, indicating the potential of ASA+BTZ in treating MM, particularly for cases of BTZ-refractory/relapsed MM.
|
28356941 |
2017 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We used the Bcl-2/Bcl-x<sub>L</sub> inhibitor ABT-737 to study the factors regulating whether myeloma is Mcl-1 dependent, and thus resistant to ABT-737-induced apoptosis, or Bcl-2/Bcl-x<sub>L</sub> codependent, and thus sensitive to ABT-737.
|
28151428 |
2017 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Multiple myeloma xenograft models that coexpressed BCL-XL or MCL-1 with BCL-2 were also resistant to venetoclax.
|
26939706 |
2016 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.
|
27465916 |
2016 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Ritonavir and metformin effectively suppressed AKT and mTORC1 phosphorylation and prosurvival BCL-2 family member MCL-1 expression in multiple myeloma cell lines in vitro and in vivo.
|
25542900 |
2015 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High BCL2 levels have been detected in most human lymphoid malignancies, not limited to follicular lymphoma (where the role of BCL2 overexpression is driven by the t[14;18] translocation) but also B-cell chronic lymphocytic leukemia (CLL) and multiple myeloma.
|
24095849 |
2014 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Myeloid cell leukemia-1 (Mcl-1, HGNC: 6943), a pro-survival member of the Bcl-2 family, plays a crucial role in Multiple Myeloma (MM) pathogenesis and drug resistance, thus representing a promising therapeutic target in MM.
|
24120758 |
2014 |